SCM
TOVX icon

Sterneck Capital Management’s Theriva Biologics TOVX Stock Holding History

Sterneck Capital Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100
Closed -$7K – 107
2021
Q4 		$7K Hold
100
– – ﹤0.01% 107
2021
Q3 		$11K Hold
100
– – 0.01% 105
2021
Q2 		$13K Buy
+100
New +$14.3K 0.01% 104

Other funds holding TOVX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Sterneck Capital Management's TOVX Position: Q1 2022 in Review

Sterneck Capital Management sold out of Theriva Biologics (TOVX) in Q1 2022, closing a stake of 100 shares — an estimated $7K sold.

Sterneck Capital Management first reported a position in TOVX in Q2 2021 and held it in 3 quarters. The position peaked at $13K in Q2 2021. 32 funds tracked by Wall St. Rank hold TOVX as of Q1 2022.

  • Sterneck Capital Management reported no remaining Theriva Biologics position as of Q1 2022 after selling out during the quarter.
  • Sterneck Capital Management sold 100 Theriva Biologics shares in Q1 2022, an estimated $7K.
  • Sterneck Capital Management first reported a position in Theriva Biologics in Q2 2021 and held it in 3 quarters.
  • Sterneck Capital Management's Theriva Biologics position peaked at $13K in Q2 2021.
  • 32 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2022.

Based on Sterneck Capital Management's 13F filing for Q1 2022, filed 3 May 2022.